[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
[junkie-alert style=”grey”] CathWorks Ltd., a leader in the development of non-invasive Fractional Flow Reserve (FFR) measurements for guiding coronary interventions, announced today the appointment of James M. Corbett as its Chief Executive Officer. Corbett, an industry veteran with broad experience in global commercialization, has served as President, Boston Scientific International, CEO Home Diagnostics, CEO of ev3 Inc, CEO of Vertos Medical and CEO of Alphatec Spine. [/junkie-alert]
The company reports that Guy Lavi, Founder of CathWorks, will continue in his role as President of CathWorks Ltd. “We are excited to have Jim join to lead the company in its efforts to globally commercialize the FFRangio technology,” said Lavi. CathWorks has made material advances of late, including the closing of Series B financing of $15.8M during August as well as the recent announcement of the first enrollment of its FDA Clinical Trial, FAST-FFR (FFRangio Accuracy vs. STandard FFR).
On the new appointment, Scott Ward, Chairman of the Board of CathWorks notes, “Having Jim join CathWorks at this point, demonstrates an important transition of CathWorks to the next stage of development. Jim brings the experience and achievement necessary to develop the global organization that can execute on the significant opportunity created by the FFRangio technology.”
The company believes that the FFRangio technology has the potential to become the standard of care in the cath lab, enhancing the diagnostic decision making of cardiologists around the world. “The CathWorks FFRangio is truly a disruptive and breakthrough technology and I am excited to be working with the CathWorks team in Israel,” said Corbett.